Dahal Lekh N, Basu Neil, Youssef Hazem, Khanolkar Rahul C, Barker Robert N, Erwig Lars P, Ward Frank J
Section of Immunology and Infection, Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK.
Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK.
Arthritis Res Ther. 2016 Aug 4;18:180. doi: 10.1186/s13075-016-1075-1.
The inhibitory CTLA-4 molecule is a crucial regulator of immune responses and a target for therapeutic intervention in both autoimmunity and cancer. In particular, CTLA-4 is important in controlling antigen-specific immunity, including responses to autoantigens associated with autoimmune disease. Here, we investigate cytokine responses to a range of lupus-associated autoantigens and assess whether the alternatively spliced isoform of CTLA-4, soluble CTLA-4 (sCTLA-4), contributes to immune regulation of autoantigen-specific immunity in systemic lupus erythematosus (SLE).
The cell culture supernatant production of sCTLA-4 as well as the cytokines IL-10, IFN-γ, and IL-17 from peripheral blood mononuclear cells (PBMC) from lupus patients and age- and sex-matched healthy volunteer donors were measured in response to previously identified histone and small nuclear ribonucleoprotein (snRNP) autoantigen-derived peptides (H391-105, H471-93, and U170K131-151) by ELISA. We also examined the functional contribution of sCTLA-4 to immune regulation in the context of these autoantigenic peptides following blockade of sCTLA-4 with a selective anti-sCTLA-4 monoclonal antibody, JMW-3B3.
We identified responses to autoantigenic peptides, which revealed qualitative differences in cytokine (IL-10, IL-17, and IFN-γ) profiles between SLE patients and healthy donors. PBMC from healthy donors responded to each of the lupus peptides by secreting IFN-γ and IL-17, but PBMC from SLE patients produced IL-10. Although we did not observe differences in the levels of serum or PBMC culture supernatant sCTLA-4 in either cohort, blockade of sCTLA-4 in PBMC cultures responding to antigen enhanced the cytokine profiles associated with each group.
The results show that lupus autoantigen-derived peptides display varied immunogenicity in lupus versus healthy volunteer donors, while sCTLA-4 acts to regulate the T-cell activity independently of response profile.
抑制性细胞毒性T淋巴细胞相关抗原4(CTLA-4)分子是免疫反应的关键调节因子,也是自身免疫性疾病和癌症治疗干预的靶点。特别是,CTLA-4在控制抗原特异性免疫方面很重要,包括对与自身免疫性疾病相关的自身抗原的反应。在此,我们研究细胞因子对一系列狼疮相关自身抗原的反应,并评估CTLA-4的可变剪接异构体可溶性CTLA-4(sCTLA-4)是否有助于系统性红斑狼疮(SLE)中自身抗原特异性免疫的免疫调节。
通过酶联免疫吸附测定(ELISA),检测狼疮患者及年龄和性别匹配的健康志愿者外周血单个核细胞(PBMC)对先前鉴定的组蛋白和小核核糖核蛋白(snRNP)自身抗原衍生肽(H391-105、H471-93和U170K131-151)的反应中sCTLA-4以及细胞因子白细胞介素10(IL-10)、γ干扰素(IFN-γ)和白细胞介素17(IL-17)在细胞培养上清液中的产生情况。在用选择性抗sCTLA-4单克隆抗体JMW-3B3阻断sCTLA-4后,我们还研究了在这些自身抗原肽的背景下sCTLA-4对免疫调节的功能贡献。
我们鉴定了对自身抗原肽的反应,揭示了SLE患者和健康供体之间细胞因子(IL-10、IL-17和IFN-γ)谱的质的差异。健康供体的PBMC通过分泌IFN-γ和IL-17对每种狼疮肽作出反应,但SLE患者的PBMC产生IL-10。虽然我们在两个队列中均未观察到血清或PBMC培养上清液中sCTLA-4水平的差异,但在对抗原作出反应的PBMC培养物中阻断sCTLA-4可增强与每组相关的细胞因子谱。
结果表明,狼疮自身抗原衍生肽在狼疮患者与健康志愿者供体中表现出不同的免疫原性,而sCTLA-4可独立于反应谱调节T细胞活性。